Castle Biosciences
CSTL
151 hedge funds and large institutions have $553M invested in Castle Biosciences in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 55 reducing their positions, and 17 closing their positions.
7% more capital invested
Capital invested by funds: $515M → $553M (+$37.8M)
2.24% more ownership
Funds ownership: 88.76% → 90.99% (+2.2%)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
2% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 55
8% less call options, than puts
Call options by funds: $3.06M | Put options by funds: $3.33M
1% less funds holding
Funds holding: 153 → 151 (-2)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$15.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.11M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$6.85M |
| 4 |
BlackRock
New York
|
+$6.8M |
| 5 |
Morgan Stanley
New York
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$11.7M |
| 2 |
Millennium Management
New York
|
-$10.2M |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$2.23M |
| 4 |
KOCAA
Knights of Columbus Asset Advisors
New Haven,
Connecticut
|
-$1.77M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.16M |
CSTL Hedge Fund Activity: Q1 2024 in Review
151 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2024, worth a combined $553M — up 7.3% from $515M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CSTL positions and 17 closed out — a net gain of 1 holder — while 54 added to existing stakes and 55 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $15.2M. The largest seller was Granahan Investment Management, cutting an estimated $11.7M.
- 151 institutional investors held Castle Biosciences (CSTL) as of Q1 2024, down from 153 in Q4 2023.
- Funds reported $553M of Castle Biosciences stock for Q1 2024, up 7.3% quarter-over-quarter.
- 18 funds opened new Castle Biosciences positions in Q1 2024 and 17 closed out, a net change of +1 holder.
- The largest Castle Biosciences buyer in Q1 2024 was Soleus Capital Management, an estimated $15.2M added.
- The largest Castle Biosciences seller in Q1 2024 was Granahan Investment Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2024.